SJL Mice: Immune Traits, MS Models, and Breeding

SJL/J mice are one of the most autoimmune-prone inbred mouse strains in biomedical research, used primarily to model diseases like multiple sclerosis, muscular dystrophy, inflammatory myopathies, and B-cell lymphoma. Originally bred from a Swiss-Webster stock at the Jackson Laboratory in the 1950s, they carry a unique combination of immune system quirks and spontaneous disease susceptibilities that make them irreplaceable in certain research areas, and frustrating to work with in others.

What Makes the SJL Immune System Unusual

The defining immunological feature of SJL mice is their MHC haplotype, designated H-2^s. This particular set of immune-recognition molecules sits on the surface of cells and helps the immune system decide what to attack. In SJL mice, the class II molecule I-A^s is unusually permissive: it presents self-derived protein fragments to T cells in ways that trigger strong autoimmune responses rather than the tolerance seen in most other strains. Research comparing SJL mice with other strains sharing related haplotypes found that I-A^s itself drives susceptibility to autoimmune reactions, and that the corresponding molecule in resistant strains actively suppresses those same responses.¹ More recently, sequencing of the I-A^s beta chain revealed a previously unrecognized amino acid substitution at a key position that affects how tightly the molecule grips peptide fragments, potentially destabilizing the whole complex and influencing both antibody responses and T cell recognition.²

Beyond the MHC, SJL mice have strikingly poor natural killer (NK) cell activity. NK cells are a first line of defense against virus-infected cells and tumor cells, and most mouse strains can ramp up NK activity in response to interferon signaling. SJL mice cannot. Studies have traced this deficit to the thymus: removing the thymus from newborn SJL pups actually restores their NK cell function, suggesting that the thymus actively suppresses NK cell development in this strain during the first weeks of life.³ This is an unusual inversion of what the thymus normally does, and it contributes to the strain’s vulnerability to both viral infections and certain cancers.

A Go-To Model for Multiple Sclerosis

The single most common reason researchers reach for SJL mice is to study experimental autoimmune encephalomyelitis, or EAE, which serves as an animal model of multiple sclerosis. When SJL mice are immunized with a fragment of myelin proteolipid protein (specifically the peptide PLP 139–151), they develop an inflammatory attack on their own central nervous system that produces episodes of paralysis, recovery, and relapse, closely mirroring the relapsing-remitting pattern seen in most human MS patients.⁴ That relapsing-remitting course is a crucial feature. Other commonly used strains like C57BL/6 develop a chronic, progressive form of EAE that does not wax and wane, which limits their usefulness for studying relapse biology or testing therapies aimed at preventing flares.

The susceptibility is partly explained by a surprisingly high number of T cells that already recognize the PLP 139–151 peptide in the naive (never-immunized) SJL mouse. In resistant strains sharing the same MHC haplotype, those self-reactive T cells are present at much lower frequencies, meaning the immune system needs a bigger push to mount an autoimmune attack.⁵ Some transgenic versions of SJL mice, engineered to carry T cells that recognize myelin oligodendrocyte glycoprotein (MOG), develop spontaneous relapsing-remitting EAE without any immunization at all, with episodes alternating between different parts of the central nervous system like the spinal cord, cerebellum, and optic nerve.⁶

This model is heavily used in drug development. EAE in SJL mice has been the testbed for modified amino acid copolymers related to glatiramer acetate (a marketed MS drug), tested in prevention, vaccination, and treatment protocols.⁷ It has also been used to screen natural compounds: female SJL mice immunized with PLP 139–151 and then treated with icariin, a plant-derived flavonoid, showed reduced inflammation and less demyelination in their spinal cords compared to untreated animals.⁸ The relapsing-remitting pattern gives researchers a natural timeline of flare and recovery against which to measure therapeutic effects, which is more clinically translatable than a one-way decline.

Viral Demyelination and Theiler’s Virus

EAE is an autoimmune model where the researcher deliberately triggers the attack. But SJL mice are also susceptible to a virus-driven demyelinating disease that arises from a different mechanism. Theiler’s murine encephalomyelitis virus, when injected into the brain, produces a chronic progressive disease in susceptible strains characterized by inflammation and gradual paralysis of the hind limbs.⁹ SJL mice are among the most susceptible. This matters because it gives researchers a second, complementary way to study demyelination: one driven by the adaptive immune system attacking self (EAE) and another driven by persistent viral infection damaging myelin-producing cells.

Genetic mapping studies have traced some of the susceptibility to a region near the T cell receptor beta-chain genes on chromosome 6, though the full genetic architecture is complex and involves multiple loci.¹⁰ Work on CD8-deficient SJL mice showed that removing CD8+ T cells made the mice even more susceptible to Theiler’s virus and worsened the demyelinating pathology, suggesting that CD8+ cells play a partial protective role in this context even though other T cell populations contribute to the damage.¹¹ The interplay between viral clearance and immune-mediated damage is a theme that runs through a lot of SJL research, and the Theiler’s virus model lays it bare.

Spontaneous Muscular Dystrophy

SJL mice carry a naturally occurring mutation in the dysferlin gene, making them one of a small number of mouse models for a group of human muscle diseases collectively called dysferlinopathies. In humans, mutations in the same gene cause limb-girdle muscular dystrophy type 2B and Miyoshi myopathy, both of which involve progressive muscle weakness and wasting due to defective membrane repair in muscle fibers.¹²

SJL mice develop a spontaneous myopathy, meaning their muscles degenerate without any experimental intervention. But there is an important caveat: because SJL mice are so autoimmune-prone, the muscle damage they show involves both the intrinsic dysferlin deficiency and an overlay of immune-mediated inflammation. This can confuse interpretation. A study of MHC class I molecules in SJL muscle found that MHC class I expression was upregulated in affected fibers, but this upregulation was not actually required for the myopathy to develop, suggesting the muscle damage proceeds even without immune amplification.¹³ Another naturally dysferlin-deficient strain, A/J, also develops myopathy, but the two strains differ in the progression rate and which muscles are most affected, as well as in their gene-expression profiles, reflecting how the broader genetic and immunological background modifies the disease.¹⁴ Researchers working with SJL mice as a dystrophy model need to account for the immune component, which makes the strain both more realistic (human muscular dystrophies also involve inflammation) and harder to interpret cleanly.

Autoimmune Myositis

Distinct from their spontaneous dysferlin-related myopathy, SJL mice can also develop experimentally induced autoimmune myositis, which models human inflammatory myopathies like polymyositis and dermatomyositis. When injected with crude muscle tissue mixed with an immune-stimulating adjuvant, nearly all SJL mice developed muscle fiber destruction accompanied by infiltrating immune cells, both within the damaged fibers and in the surrounding connective tissue. Eight other mouse strains with different MHC types, immunized in the same way, failed to develop the disease.¹⁵ This strain specificity reinforced the role of the H-2^s haplotype in driving autoimmune susceptibility across multiple tissue targets.

A refined version of the model uses purified rabbit myosin to immunize SJL mice, producing elevated anti-myosin antibodies and complement deposition on muscle fibers. Intravenous immunoglobulin treatment in these mice reduced both antibody levels and complement-mediated damage, offering a mechanistic rationale for a therapy already used empirically in human myositis patients.¹⁶ The fact that SJL mice are uniquely susceptible to both induced myositis and spontaneous myopathy makes them a convergence point for muscle disease research, though it also means researchers have to be careful about which pathology they are actually measuring.

Near-Universal B-Cell Lymphoma

Perhaps the most striking spontaneous disease in SJL mice is their extraordinary rate of B-cell lymphoma, historically called reticulum cell sarcoma (RCS). Over a two-year lifespan, more than 90–95% of SJL mice develop these tumors.¹⁷ The tumors originate from germinal center B cells and depend on an endogenous retroviral superantigen (encoded by an integrated mammary tumor virus, mtv-29) that stimulates a specific population of T cells to produce growth-promoting cytokines.¹⁸ This creates a feedback loop: the superantigen activates T cells, the T cells produce cytokines, and those cytokines feed the B-cell tumor.

The genetics behind this susceptibility have been partially mapped. When SJL mice are crossed with other strains carrying the same H-2^s haplotype but lacking the lymphoma susceptibility, the F1 offspring show almost no RCS, dropping from over 90% to single-digit incidence. This pointed to a dominant suppressor gene in the resistant strain rather than a simple recessive susceptibility gene in SJL.¹⁹ When the tumor suppressor gene p53 is knocked out in SJL mice, tumors arise even faster and the spectrum of tumor types broadens, making these p53-null SJL mice a potential screening tool for chemotherapy and immunotherapy candidates.²⁰

For researchers using SJL mice in non-cancer studies, the near-certain development of lymphoma sets a practical ceiling on how long experiments can run. Any study extending past about 12 months needs to account for the possibility that aging SJL mice may already be developing subclinical tumors that could influence immune function, blood chemistry, or behavior.

Airway Hypersensitivity Research

The autoimmune and cancer applications get most of the attention, but SJL mice also show up in allergy research. Passive sensitization experiments, where allergen-specific IgE antibodies are injected intravenously, demonstrated that SJL mice develop both immediate skin reactions and increased airway responsiveness after allergen challenge, similar to what was seen in the more commonly used BALB/c strain.²¹ The ability to transfer hypersensitivity passively through antibody injection makes both strains useful for dissecting which immune components are sufficient to produce an allergic response, independent of the full immunization process. SJL mice are not the default choice for asthma research, but their inclusion in these studies helps establish that findings are not artifacts of a single genetic background.

Aggression and Colony Management

Anyone who has housed SJL mice knows they fight. Male SJL mice are among the most aggressive of commonly used inbred strains, and managing group-housed males often requires careful attention to cage composition and enrichment. A study examining chemical signals in urine, plantar foot sweat, and nesting material across multiple strains found that SJL cages displayed the most aggression, with distinctive chemical patterns in their urine and nesting material that correlated with agonistic behavior.²² This is not merely a husbandry nuisance. The chronic stress from fighting can alter immune function, wound healing, and hormone levels, all of which introduce variability into experiments. Many labs separate male SJL mice into individual housing as a standard practice, though this creates its own confound because social isolation also affects physiology.

Female SJL mice are substantially less aggressive and are the standard choice for EAE experiments, partly because the disease course is more consistent in females and partly because group housing is far less problematic. This sex bias in experimental use means that many published findings on SJL immune responses are drawn predominantly from female mice, which is worth keeping in mind when generalizing results.

Breeding Challenges

SJL mice are not the easiest strain to breed. Like many inbred strains, they show reduced reproductive performance compared to outbred stocks, but SJL mice have particular issues. A comparative study of ten inbred strains found significant differences in superovulation response, in vitro fertilization success, and the number of live pups born after embryo transfer, with genetic variability across strains driving much of the variation.²³ The strain’s tendency toward aggression, early lymphoma development, and spontaneous myopathy all impose practical constraints on breeding colony management. Labs that rely on SJL mice typically maintain relationships with commercial suppliers (Jackson Laboratory, Charles River, and others) rather than running large breeding colonies in-house, because the overhead of maintaining healthy, age-matched cohorts is substantial.

Retired breeders and aged SJL mice are sometimes repurposed for lymphoma or aging studies, but their utility is limited by the fact that by the time they are retired, many are already developing one or more of the strain’s spontaneous pathologies. This telescoping of multiple disease susceptibilities into a single genetic background is what makes SJL mice so powerful for certain experiments and so tricky for others. Any researcher using them needs to know not just what they are studying, but what else the mice might be developing in the background.

When SJL Mice Are the Wrong Choice

The same features that make SJL mice valuable for autoimmune and cancer research make them a poor fit for studies where you need a clean immunological baseline. Their defective NK cells, hyperactive T cell repertoire, spontaneous myopathy, and near-certain lymphoma development all introduce confounds. If you are studying, for example, a novel vaccine and want to see a normal immune response in a healthy animal, SJL mice will give you a distorted picture. Similarly, long-term toxicology studies are complicated by the fact that SJL mice are already developing serious pathology on their own timeline.

The strain is also a reminder that findings in one mouse background do not automatically transfer to another. A drug that suppresses EAE in SJL mice may fail in C57BL/6 mice immunized with a different myelin peptide, and vice versa. The field has learned to test across multiple strains and multiple disease induction protocols before drawing broad conclusions about therapeutic potential. SJL mice occupy a specific niche: relapsing-remitting autoimmunity, dysferlin-related myopathy, superantigen-driven lymphoma, and the complex interplay among all three. Within that niche, no other strain does quite what they do.